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It was   the  purpose  of this study to investigate  the effects  of 
an  oral contraceptive on the  submaximal work performance  of college 
women.     It was hypothesized that  an oral contraceptive would have no 
significant  effect   on performance  at  submaximal work loads  of 300  and 
600 Kpm for  any phase  of  the menstrual cycle. 
Eleven female  subjects from the  sophomore class   (1974)   at  the 
University of North  Carolina at Greensboro were volunteers  for this 
experiment.     Open  circuit  respirometry was utilized  to  investigate 
the extent to which the  aerobic function of women was  influenced by 
an  oral contraceptive.     The  subjects  performed  submaximal work at   in- 
tensities  of 300 and 600 Kpm on a Monarche bicycle ergometer.     Oxygen 
consumption was determined using a Beckman OM-11 breath by breath 
oxygen analyzer.     Pretest  measurements were recorded  for each subject 
on the  4th,   10th,   and 26th day of her menstrual  cycle one month prior 
to taking an oral contraceptive.     A post-test was  given to each subject 
on the  4th,   10th,   and 26th day of the menstrual cycle while taking 
birth control pills. 
Results  indicated  that  increases  in the metabolic work of the 
exercise  took place  for all phases of the menstrual  cycle but  reached 
a significant  level  for the  4th and 26th day of the  cycle. 
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CHAPTER I 
INTRODUCTION 
The birth  control pill is  the most extensively used contraceptive 
in our society today   (6).     Studies have been conducted  to examine the 
various pharmacological effects  associated with this type  of  contracep- 
tive, however,  these studies have not  generally been concerned with the 
physical performance of non-athletes.     Oral contraceptives have been 
used to manipulate the menstrual cycle of  female  athletes,   in  order to 
allow them to participate in various  international  competitions, with 
no regard to the  physiological responses these drugs may produce with 
respect to athletic performance   (9,11).     At  this  time,  there appears to 
be a paucity  of studies reporting the effects of oral  contraceptives 
on the aerobic  capacity of  female, non-athletes.     However, Udry and 
Morris  studied  the effects   of  contraceptive pills on physical activity 
(10).     A total of  thirty-four women wore pedometers every day until 
bed-time for three   complete menstrual cycles.     One group of  eight women 
took  an oral contraceptive and  the other group of  twenty-six women 
acted  as  a  control  and took no contraceptive.     The general physical 
activity level  of  the women  taking contraceptive pills was  lower than 
that   of the women not taking pills.     The investigators  suggested  that 
since  subjective  fatigue  and depression are widely recognized as side 
effects of the  pills,  it  seemed reasonable to interpret  the significant 
difference in pedometer readings as objective  evidence of a depressant 
physiologic effect. 
Related Literature 
There  are   apparently no studies reporting the effects  of an oral 
contraceptive  on the  aerobic capacity of  female non-athletes.     However, 
there has been extensive research as  to the effects  of  oral  contracep- 
tives  on metabolism.     The literature in this area is   confusing to 
interpret because of the lack of   consistent experimental design.     In 
addition,   the types  of subjects,   drugs,  dosages,   and treatment  periods 
have been varied by  different  investigators.     In this  chapter  there 
will be  an attempt to review studies dealing with the effects  of  com- 
bination type oral contraceptives  on  carbohydrate and lipid metabolism. 
Carbohydrate Metabolism 
In 1966 Wynn and Doar  investigated  carbohydrate metabolism in a 
group  of 105 women taking oral contraceptives for three months and  in 
a control group  of seventy-eight women   (20) .    Eighteen percent   (15 
women)   of  oral  and fifteen percent   (12 women) of intravenous glucose 
tolerance test were  found to be  abnormal in  the experimental group. 
The mean fasting-plasma-glucose was unchanged.     Elevated  fasting 
plasma non esterified  fatty acid   (N.E.F.A.)   levels were noted and the 
fall after glucose  administration was delayed.    The most  striking 
change  observed was an increase in the maximum plasma pyruvate levels 
following the administration of glucose.     This occurred in about  20% 
of  the women in the test  group.     The investigators were uncertain as  to 
whether the  increased pyruvate levels were due to increased  rates  of 
production or impaired  removal of  the metabolite.    Wynn and Doar 
conducted  another study in  1969  and  reported  results similar to those 
found  in  their  first  study   (19).     Sixty-seven women were tested before 
using oral contraceptives  and  again while  receiving  oral contraceptive 
therapy.     Eight  different  estrogen-progestogen combination oral  contra- 
ceptives were used  for the experiment.     Subjects were tested   serially 
for twenty-three months.     Results  showed  impaired  oral and intravenous 
glucose-tolerance  and  elevated venous blood pyruvate   levels both before 
and  after oral/intravenous  glucose administration.     The investigators 
were unable  to determine whether the  increased   fasting blood pyruvate 
levels were due  to an increased  rate of   formation or  impaired  degrada- 
tion.     No  relationship was  found between impaired glucose tolerance, 
increased   fasting pyruvate  levels  and duration of  therapy, day of  cycle, 
or  type  of estrogen progestogen combination.     Cramp, Wynn and Doar 
substantiated these  findings  in a study  also  conducted in 1969   (4). 
They  administered  oral and intravenous  glucose  tolerance tests to 129 
women receiving oral contraceptive therapy.     All subjects consumed at 
least  200  grams  of  carbohydrate  for three days before each test. 
Several different   types  of  combination  oral contraceptives were used 
in the experiment  and the mean duration  of the therapy was eighteen 
months.     Mean venous blood pyruvate levels were significantly elevated 
in the subjects of  the test group in the fasting state and during oral 
and intravenous glucose tolerance  tests.     No relationship between the 
fasting blood pyruvate  level and type of estrogen-progestogen  combina- 
tion oral  contraceptive,  duration of therapy,  or day of cycle was 
found.     No significant  correlation was found between the rate  removal 
constant   (Kx)   for  lactate,  and the fasting blood  lactate level. 
According to the  investigators,   these findings suggest  that  the 
elevated  fasting blood pyruvate and lactate  levels  found in some 
subjects  receiving  oral contraceptive  therapy are due to increased 
rates  of production rather than  impaired removal  of the metabolites. 
In 1971 Spellacy,  Buhi, Burk,   and McCreary administered an oral 
glucose tolerance test  to 54 women before taking  an  oral  contraceptive 
and  then repeated  serially during  therapy for a year.     There was   a 
significant elevation  of  the mean glucose values  after the use of the 
drug   (15). 
Spellacy's  study  completed  in 1972 confirmed  these findings   (16). 
Thirty-seven women had a 3-hour   (lOOgm)   oral glucose  tolerance test 
performed  on two different  occasions.     The first test   (control)  was 
at  least  four weeks  post partum and before any steroid  contraceptive 
was  administered.     The women were then given  a combination type oral 
contraceptive to take  in the cyclic manner.     The  second test was  carried 
out  in an  identical manner  during the sixth month of  oral  contraceptive 
treatment.     All  of  the mean blood glucose values were elevated  in asso- 
ciation with oral contraceptive usage. 
Lipid Metabolism. 
In 1969 Wynn and Doar investigated  fasting serum triglyceride and 
cholesterol levels in a group of 68 women before and during oral contra- 
ceptive therapy   (18).     Several different  types  of  combination oral 
contraceptives were used for the experiment.     Samples of venous blood 
were taken after  an overnight fast  of at  least  twelve hours.    The mean 
duration  of the  study was six months.    The mean fasting serum triglyceride 
level was  increased during oral contraceptive therapy, but   the mean 
fasting serum cholesterol level was unchanged.     As pointed   out by the 
investigators,  it   is not known whether the elevated serum triglyceride 
levels  are due to an increased rate of production or impaired removal 
from the  circulation.     No relationship was  found between the change  of 
serum triglyceride  level and  the duration of therapy, nature of estrogen- 
progestogen  combination or  the day  of  the treatment cycle.     Sach, Wolfman, 
and Herzia found similar results in their study also conducted  in 1969   (12), 
Nineteen women were studied   for periods of 6-18 months.    After an initial 
control period of one month the  subjects were given a combination type 
oral  contraceptive.     By the  4th week of oral contraceptive usage twelve 
women showed  significantly increased  triglyceride levels.     Of  the nine- 
teen women studied,  sixteen showed progressive increases  in plasma tri- 
glyceride  levels up  to six weeks which then  attained a plateau.     The 
nineteen women patients,   as a  group,  showed a mild but  statistically 
insignificant rise in cholesterol  levels.     A rise  in serum triglyceride 
and  cholesterol in women taking a combination type oral contraceptive 
was  also  found by Barton,  Freeman,   and Lawson in   1970   (2).     One hundred 
and seventy-three subjects were tested  at three monthly  intervals for 
two years.     The rise in serum cholesterol and triglyceride in the subjects 
began early and was maintained  as long  as the use  of contraceptives were 
continued.     These findings were substantiated in  a study conducted in 
1971 by Stokes and Wynn  (17).     Fasting serum-lipid  levels were studied 
in 525 women on a combination  oral contraceptive.     Control subjects were 
studied before  starting on oral  contraceptives and all the  other subjects 
were  investigated while receiving an oral  contraceptive.    Elevated mean 
fasting serum-triglyceride  levels were  found  in women on oral contra- 
ceptives.     Increased values   of mean fasting cholesterol was   also found 
in women during oral contraceptive usage. 
As shown  in the review of literature,   oral  contraceptives can alter 
carbohydrate metabolism and  often result  in elevation of blood glucose 
levels  and an  increase  in fasting blood pyruvate levels.     Investigators 
are uncertain as  to whether the increased  fasting blood pyruvate levels 
are due  to an increased rate of production or  impaired degradation. 
As evidenced in the  literature,  oral contraceptives can also alter 
lipid metabolism.     The most marked  alteration is the elevation of  the 
blood levels  of triglycerides. 
According  to Spellacy, who reviewed the metabolic effects of oral 
contraceptives in 1974,  the mechanism for producing these  changes  in 
metabolism appears multifactorial but may include alteration of liver 
function,  excessive production of pituitary growth hormone  or increase 
in free  active cortisol   (14). 
Apparently,  there has been no research concerning the possible 
effects  of  these metabolic changes which accompany oral contraceptive 
usage,  on the physical performance of female athletes. 
Statement  of Problem 
The purpose of  this  study was to determine  the effects  of an oral 
contraceptive  on the submaximal work performance of  college women.     A 
significant difference at  the   .05  level of confidence will be used as 
the criterion to determine whether the following six null hypotheses  are 
tenable. 
1. An oral contraceptive has no significant effect on performance 
at  a submaximal work load of  300 Kpm on the  4th day of  the 
menstrual cycle. 
2. An oral contraceptive has no significant effect on performance 
at  a submaximal work load of  600 Kpm on the  4th day of   the 
menstrual cycle. 
3. An oral contraceptive has no  significant effect on performance 
at  a submaximal work load of 300 Kpm on the  10th day of  the 
menstrual cycle. 
4. An  oral  contraceptive has no significant effect   on performance 
at a submaximal work load of 600 Kpm on the 10th day of the 
menstrual cycle. 
5. An  oral contraceptive has no  significant effect  on performance 
at a submaximal work load of 300 Kpm on the  26th day of the 
menstrual cycle. 
6. An oral  contraceptive has no significant  effect   on performance 
at  a submaximal work load of 600 Kpm on the 26th day  of the 
menstrual  cycle. 
Definition of Terms 
For  interpretation in this study,  the following definitions are 
offered: 
Oxygen consumption— a measure of  the energy  cost  of  steady state 
work at 300 Kpm and  600 Kpm. 
Oral contraceptive- a drug in tablet  form, which  chemically controls 
fertility by preventing ovulation. 
Combination  oral  contraceptive— an oral contraceptive which 
contains a  combination of  two  female sex hormones,  estrogen and 
progesterone,   in each  tablet. 
Basic Assumptions 
The   investigation made the following basic assumptions: 
1. It was  assumed  that all of the subjects  responded in a similar 
manner while  taking oral contraceptives. 
2. That the differences in dosage  of the hormones produced by the 
different weights of the subjects did not influence the results 
of the  study. 
3. That the effects of variables other than oral contraceptives 
on oxygen  consumption would be randomly distributed among the 
subjects. 
CHAPTER II 
METHODS   AND PROCEDURES 
The purpose of  this  study was  to determine the effects of  an oral 
contraceptive  on the submaximal work performance of   college women.     The 
procedures   outlined in this chapter describe the methodology used. 
General Procedures 
Fifteen volunteers were recruited from the female student population 
enrolled   in  the Fall of  1974 at the Greensboro  campus of the University 
of North  Carolina.     Selection of the subjects was based upon the following 
criteria: 
a. They were  in the  age range  of 19-20 years. 
b. They never had taken birth control pills. 
c. They agreed to maintain their normal exercise regime for the 
duration of the  study. 
d. They agreed not   to take any stimulants  or depressants 24 hours 
prior to being tested. 
e. They were  in good health and went to the  campus  infirmary to 
be examined by a physician, who agreed   to assist with this 
portion of  the study. 
Tvo subjects withdrew from the experiment because of parental disap- 
proval.     Also,  two subjects were unable to finish the  study because of 
conflicts  in the testing  schedule. 
The extent  to which  the aerobic  function of women was   influenced by 
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oral  contraceptives was  investigated   on open circuit respirometry.     The 
participants  performed  submaximal work at  intensities of  300 and 600 Kpm 
on a Monarche Bicycle Ergometer.     Oxygen  consumption was determined using 
a Beckman OM-11,  breath by breath oxygen  analyzer.     Steady state heart 
rate was determined by recording the  electrocardiogram  (E.C.G.)   on an 
ink writing polygraph. 
Each subject was  tested on the 4th,   10th,  and 26th day of her menstrual 
cycle, with the first day of menstrual  flow being designated  as day one. 
These particular days were  chosen arbitrarily with the  intent  of  testing 
the subjects  at  the beginning,  in the middle,  and at  the end  of  their 
menstrual cycle.     The subjects were tested  one month prior to taking birth 
control pills  and while  taking pills. 
Organization of Testing Sessions 
Each subject  attended  the  campus  infirmary for an examination by a 
physician  in order to receive a two month's  supply of  the Norlestrin 
birth  control pill.     Following the examination,  the physician gave 
specific instructions  as  to how the birth control tablets were to be 
taken.     He also  informed the  subjects  that morning sickness, weight  gain, 
and acne were  frequent side effects. 
Norlestrin 21,  1 mg.   is a progestogen-estrogen  combination oral 
contraceptive.     The  selection of  this particular oral  contraceptive was 
based on its  routine prescription at the campus infirmary. 
Each participant  contacted the investigator by phone  at the onset 
of her menstrual  cycle.     A testing schedule was  arranged  for the 4th, 
10th,  and  26th day of her menstrual  cycle.     After the   completion of  the 
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pre-tescs each  subject began  taking her first series of birth control 
pills during  the next menstrual cycle as  directed by the physician. 
Each subject began taking birth control  tablets on day 5, with the 
first day of menstrual  flow being designated  as day 1,  and continued 
taking one tablet daily for 21 days.     She then took no tablets for 
seven days.     The contraceptive action of the pill is established  after 
the 21st  tablet has been taken   (5,6).     Therefore, each subject,  as 
instructed,   contacted the  investigator by phone several days before the 
21st  tablet was taken.     A time was then arranged for the subject  to be 
tested  the day  after the 21st  tablet was  taken, which was  the 26th day 
of her menstrual cycle.     After the  seven days  in which no tablets were 
taken,   each subject began  taking  another series of birth control pills. 
At the onset  of the menstrual  cycle each participant   again notified 
the investigator and  a testing schedule was  arranged for the  4th and 
10th day of her menstrual cycle. 
The exact procedure and nature of the study was explained to each 
subject;   they were provided with an opportunity to practice on the 
bicycle ergometer  to become  familiar with its operation.    Laboratory 
procedures  and  techniques were demonstrated and discussed with each 
subject  in order to reduce  test  confusion and expedite data collection. 
Each subject was  instructed to bring two participants with her to 
each testing  session to  assist with data collection.     In assisting with 
data collection,   one  of the participants recorded the volume of air 
inspired by the subject  and the other participant recorded the volume 
of  respired  oxygen. 
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Testing Procedures 
Each subject  entered  the  lab  and weighed herself.     The electro- 
cardiogram  (E.C.G.)   leads were placed in  the standard V^ position   (on 
the body of the sternum and at   the  intersection of  the mid  clavicular 
line  and the 5th intercostal space).     The  following adjustments were 
made for each subject on the bicycle ergometer and  its  associated 
apparatus:     first,   the height  of the seat  on the bicycle ergometer 
was adjusted so that the right  leg of the  subject was   fully extended 
when  the  crank on the bicycle ergometer was  completely vertical;   secondly, 
the position of the mouthpiece   for oxygen uptake was  adjusted to enable 
the subject to sit   in a comfortable,  upright  position on the bicycle 
ergometer and inhale  through the Adlens triple  "j" valve.     Resting heart 
rate was determined by recording the electrocardiogram on an ink writing 
polygraph.     The work load on the bicycle ergometer was regulated to 0 Kpm 
in order for  the  subject to  adjust her rate  of pedaling to the  cadence 
set by  the metronome.     The metronome was set   at a cadence of 100 beats 
per minute.     Once the subject was  able to maintain the speed  of pedaling 
set by the metronome,   the work load on the bicycle ergometer was changed 
to a submaximal work load of  300 Kpm.     Heart  rate was monitored every 
30 seconds;  when steady  state heart   rate was reached oxygen  consumption 
measurements were made every  30 seconds for Us minutes.     The work load 
on the bicycle ergometer was   then changed to 600 Kpm and  the oxygen con- 
sumption was  determined  after steady state heart  rate had been achieved 
in a manner similar to that described   above.     All measurements were 
converted  to  standard temperature and pressure. 
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CHAPTER III 
RESULTS 
The data analysis in this chapter are the results of an investi- 
gation of the effects of an oral contraceptive on the submaximal work 
performance of college women. The raw data is recorded in APPENDIX A 
and APPENDIX B. 
Eleven female subjects  from the sophomore class at   the University 
of North Carolina at Greensboro were volunteers  for this experiment. 
The participants  performed  submaximal work at  intensities  of   300 and 
600 Kpm on a Monarch bicycle ergometer.     Oxygen consumption was deter- 
mined using a Beckman OM-11 breath by breath oxygen analyzer.     Each 
subject was given  a pretest on the 4th,  10th,   and 26th day of her 
menstrual cycle  one month prior to taking an oral contraceptive.     A 
post-test was  given to each subject on  the 4th,  10th,  and 26th day of 
her menstrual  cycle while  taking Norlestrin birth control pills. 
Six null hypotheses were developed  and a significant difference 
at the  .05  level of confidence was determined  as an adequate  criterion 
for determining whether the null hypotheses were tenable.     The  six null 
hypotheses were: 
1. An oral  contraceptive had no significant effect  on performance 
at  a submaximal work load of 300 Kpm on the 4th day of the 
menstrual  cycle. 
2. An oral contraceptive had no significant effect   on performance 
at a submaximal work load of 600 Kpm on the 4th day of  the 
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menstrual cycle. 
3. An oral contraceptive had nc significant effect on performance 
at   a submaximal work load of 300 Kpm on the 10th day of the 
menstrual cycle. 
4. An  oral  contraceptive had no significant effect on performance 
at  a submaximal work load   of 600 Kpm on the 10th day of  the 
menstrual cycle. 
5. An oral contraceptive had no significant effect on performance 
at  a submaximal work load  of 300 Kpm on the  26th day of the 
menstrual  cycle. 
6. An oral contraceptive had no significant  effect  on performance 
at  a submaximal work load  of 600 Kpm on the 26th day of the 
menstrual cycle. 
Pretest  and Post-test  Scores 
Fisher's  "t" for significance   of differences between  correlated 
mean differences was used  to examine  the differences between the pretest 
and post-test  scores.     The results were: 
1. The null hypothesis  that  an oral  contraceptive had no signifi- 
cant  effect on performance  at  a submaximal work load of 300 Kpm 
on the 4th day of the menstrual  cycle was  found tenable. 
2. The null hypothesis that  an oral  contraceptive had no signifi- 
cant  effect  on performance  at a submaximal work load of  600 Kpm 
on the  4th day  of the menstrual cycle was rejected. 
3. The null hypothesis  that  an oral contraceptive had no signifi- 
cant  effect  on performance  at a submaximal work load of 300 Kpm 
^ 
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on the  10th day of  the menstrual cycle was found  tenable. 
4. The null hypothesis  that  an oral contraceptive had no signifi- 
cant   effect  on performance at  a submaximal work  load  of 600 Kpm 
on the 10th day of  the menstrual  cycle was  found tenable. 
5. The null hypothesis that  an oral contraceptive had no signifi- 
cant  effect on performance at  a submaximal work load of 300 Kpm 
on the  26th day of  the menstrual cycle was  rejected. 
6. The null hypothesis that   an oral  contraceptive had no signifi- 
cant  effect  on performance at  a submaximal work load of  600 Kpm 
on the  26th day of the menstrual   cycle was found  tenable. 
The results  are presented  in TABLE I. 
TABLE  I 
Mean Differences and Significance of  Difference 
Between Scores Pretest and Post-test 
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Time Work Load      Pretest Mean 
Kpra 
Post-test Mean 
4th day 
of cycle 
4th day 
of cycle 
10th day 
of cycle 
10th day 
of  cycle 
26th day 
of cycle 
26th day 
of  cycle 
V0    ml/kg/min      VO    ml/kg/min 
«D 
300 
600 
300 
600 
300 
600 
17.27 
25.96 
18.24 
26.30 
17.20 
27.32 
17.94 -.6791 -1.1725 
28.53 -2.5727 -2.5699* 
18.27 -.0355       -.0842 
26.05 -1.7500 -1.8941 
18.55 -1.3500 -2.5932* 
29.07 -1.7573 -1.8785 
N-ll * A t greater  than or equal to 2.228 was necessary for 
significance  at  the 0.05 level of confidence. 
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CHAPTER IV 
DISCUSSION 
This study  focussed upon one possible effect of oral  contraceptives 
on the  activity  capability of women.     The  rationale  for investigating 
this area is supported  in the review of the literature;   several metabolic 
changes  are produced  by oral  contraceptive  usage.     It has been demonstra- 
ted that carbohydrate metabolism is  impaired by the use of oral contra- 
ceptives   (A,15,19,20) .     Since carbohydrate metabolism is the primary 
energy source  in aerobic activities,   and submaximal work at  intensities 
of  300 and 600 Kpm was  selected  for  this study,   it would seem reasonable 
to assume  that  a decrease  in the efficiency of  carbohydrate metabolism 
would be  reflected by an increase in  the energy cost  of standard work 
loads during the  period of  time  oral contraceptives were used.     The 
results of  this study  did,   in fact,   indicate that such increases   took 
place  at  all phases  of  the menstrual cycle, but  reached a significant 
level for  the  4th day  and  the  26th day of the cycle.     Although not 
significant,  all  increases  in the metabolic work of the exercise,  except 
for  that  observed  for  the 300 Kpm work load on day 10, were quite large. 
A very small  increase was observed  for  day 10;  this is atypical of  the 
responses  for  the  other phases of  the menstrual cycle.     The  author  is 
unable to offer  any explanation for the phenomena at this  time. 
Several  investigators  found pyruvate levels  to be significantly 
elevated   in the  fasting state and during oral and intravenous  glucose 
tolerance  tests in subjects receiving oral contraceptive therapy   (4,19,20), 
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This suggests  that   liver function is  impaired with oral  contraceptive 
usage since pyruvate metabolism takes place mainly  in the  liver.     It 
might be  of value  to study recovery rate  after anaerobic activities 
since both lactate and pyruvate are produced during anaerobic work and 
their metabolism is  predominantly in the liver.     As such,  a significant 
increase  in recovery  time would support the thesis  that  liver function 
is impaired with oral contraceptive usage.     However,  it has been suggested 
that the  elevated pyruvate levels  reflect  an increase  in production of 
pyruvate rather than  a decrease  in its rate removal  constant   (A).     An 
increased production  of pyruvate would indicate an increase  in the 
general metabolic rate which would be reflected by an increase  in the 
energy cost  for any given work load.     These general  increases were ob- 
served  for all phases  of the menstrual cycle, but reached significance 
on day A and day 26  only.     The fact  that pyruvate levels were reported 
to be elevated  in the  fasting state  indicates an increase  in resting 
or baseline metabolic  rate.     A higher resting metabolic rate would 
result  in  a higher energy  cost   for any work load, although the energy 
cost  of  the work may remain  constant.     An investigation of the effects 
of oral contraceptives   on basal metabolism might  indicate whether the 
increase  in resting metabolic rate  is   due to a higher basal metabolic 
rate or an increase  in metabolism of   the skeletal musculature.    No 
significant  increase in the basal metabolic rate would suggest  that  the 
increase  in resting metabolic rate  is   due to a higher rate  of metabolism 
in the skeletal musculature. 
If both carbohydrate metabolism and general metabolic levels are 
altered by using oral contraceptives,   then the degrees which one or 
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both of   these phenomena contribute  to the increased energy cost  of  the 
exercise   could not  be determined   from the results of the present 
experiment. 
A rise  in serum triglyceride and  cholesterol  in women taking oral 
contraceptives was   reported by several  investigators   (2,12,17).     The 
work performed by  subjects   in this  study was of  relatively short 
duration therefore   the role  of  free fatty acids  as a preferred  substrate 
would be minimal.     It  could be  argued  that  this increase might prove 
to be beneficial for athletes  competing  in endurance  type activities 
where fats  play  an   important  role  in the  total energy production. 
Suggestions  for Further Study 
As  suggested earlier,   it might be of value to study recovery rate 
after  anaerobic activities  since both lactate and pyruvate are produced 
during anaerobic work and  their metabolism takes place mainly in the 
liver.     A significant  increase in recovery time would support  the  thesis 
that   liver   function  is  impaired with oral contraceptive usage.     In view 
of the fact  that  a rise in free  fatty acids in subjects  taking  oral 
contraceptives was   reported  in the  literature,  it might be of value  to 
study  the effects  of  oral contraceptives on prolonged physical perform- 
ance since  fats play  a major role in supplying the energy needed  for 
endurance  type activities.     Also,  as discussed earlier,  in the review 
of literature resting metabolic rate was   found to be  increased with 
oral contraceptive usage.     An investigation of oral contraceptives on 
basal metabolism might   indicate whether  the increase in resting metabolic 
rate  is    due  to a higher basal metabolic rate or an increase in metabolism 
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of skeletal musculature.     No  significant increase in the basal 
metabolic rate would suggest  that   the   increase in resting metabolic 
rate is due  to a higher rate of metabolism in the skeletal muscula- 
ture. 
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APPENDIX K 
PRETEST  RAW DATA 
Subject Weight Time               VO, ml/kg/min 
at  300 Kpm 
V02 ml/kg/min 
at 600 Kpm 
1 50.9 kgs 4th day 
of cycle 
22.79 35.36 
1 50.5 kgs 10th day 
of  cycle 
25.94 32.28 
1 51.8 kgs 26th day 
of   cycle 
21.33 37.55 
2 70.5 kgs 4th day 
of   cycle 
11.49 15.18 
2 70 kgs 10th day 
of   cycle 
14.43 17.71 
2 70.9 kgs 26th day 
of cycle 
14.04 17.57 
3 64 kgs 4th day 
of  cycle 
17.03 20.16 
3 64  kgs 10th  day 
of  cycle 
16.09 20.89 
3 65 kgs 26th day 
of  cycle 
14.12 21.38 
4 61.1 kgs 4th day 
of   cycle 
16.55 24.76 
4 61.4 kgs 10th day 
of cycle 
17.85 25.26 
4 64.1 kgs 26th day 
of cycle 
17.78 26.68 
APPENDIX A (Continued) 
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Subject Weight Time VO2 ml/kg/min 
at 300 Kpm 
V02 ml/kg/min 
at 600 Kpm 
5 80 kgs 4th day 
of  cycle 
10.63 18.63 
5 80 kgs 10th day 
of cycle 
11.59 17.56 
5 80 kgs 26th day 
of cycle 
9.225 18.80 
6 66.14 kgs 4th day 
of cycle 
14.36 25.11 
6 65.1 kgs 10th day 
of  cycle 
15.93 25.36 
6 65.23 kgs 26th day 
of cycle 
15.33 24.99 
7 48.9 kgs 4th day 
of  cycle 
20.51 37.42 
7 49.1 kgs 10th day 
of cycle 
19.45 38.35 
7 49.9 kgs 26th day 
of  cycle 
21.00 37.49 
8 52.3 kgs 4th day 
of  cycle 
19.32 28.70 
8 51.8 kgs 10th day 
of cycle 
17.84 28.96 
8 51.7 kgs 26th day 
of  cycle 
18.53 28.57 
9 49.5 kgs 4th day 
of   cycle 
20.36 22.63 
9 49.6 kgs 10th day 
of   cycle 
18.38 22.63 
APPENDIX A  (Continued) 
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Subject Weight Time VO, ml/kg/min 
at 300 Kpm 
V02 ml/kg/min 
at  600 Kpm 
10 
10 
10 
11 
11 
11 
49.5 kgs 
46.8 kgs 
48.8 kgs 
47.7  kgs 
52.3 kgs 
52.4 kgs 
52.2 kgs 
26th day 
of  cycle 
4th day 
of   cycle 
10th day 
of   cycle 
26th day 
of  cycle 
4th day 
of cycle 
10th day 
of cycle 
26th day 
of   cycle 
20.20 
17.95 
24.86 
19.48 
18.93 
18.26 
18.11 
27.07 
27.93 
34.98 
32.70 
29.63 
25.35 
27.67 
All V02 measurements were  converted  to standard temperature and pressure. 
APPENDIX  B 
POST-TEST  RAW  DATA 
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Subject Weight Time V02 ml/kg/min 
at 300 Kpm 
V02 ml/kg/min 
at 600 Kpm 
i 51.4 kgs 4th day 
of  cycle 
22.00 38.16 
i 51.4 kgs 10th day 
of  cycle 
25.76 33.39 
i 51.8 kgs 26th day 
of cycle 
21.44 37.67 
2 71.4 kgs 4th day 
of cycle 
15.41 24.66 
2 71.8 kgs 10th day 
of cycle 
15.10 24.58 
2 71.4 kgs 26th day 
of  cycle 
17.43 25.64 
3 65.5 kgs 4th day 
of  cycle 
18.15 27.23 
3 65.5 kgs 10th day 
of cycle 
18.20 27.39 
3 65.5 kgs 26th day 
of cycle 
17.11 26.43 
4 64.5 kgs 4th day 
of  cycle 
16.46 24.29 
4 65 kgs 10th day 
of cycle 
17.49 26.85 
4 64.6 kgs 26th day 
of cycle 
17.01 24.38 
APPENDIX B   (Continued) 
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Subject Weight Time V02 ml/kg/min V02 ml/kg/min 
at   300 Kpm at 600 Kpm 
5 80.9 kgs 4th day 
of cycle 
12.95 19.72 
5 80.5  kgs 10th day 
of cycle 
13.19 19.75 
5 79.5 kgs 26th day 
of cycle 
13.60 18.86 
6 65.7 kgs 4th day 
of  cycle 
16.05 26.00 
6 65.5 kgs 10th day 
of cycle 
16.72 26.77 
6 65.5 kgs 26th day 
of cycle 
16.33 26.54 
7 50.7  kgs 4th day 
of  cycle 
19.14 37.23 
7 50.8 kgs 10th day 
of cycle 
19.55 37.45 
7 50.9 kgs 26th day 
of  cycle 
20.59 36.71 
8 52.8 kgs 4th day 
of  cycle 
18.53 28.86 
8 52.3 kgs 10th day 
of  cycle 
16.89 28.47 
8 52.8 kgs 26th day 
of cycle 
18.53 28.75 
9 50 kgs 4th day 
of   cycle 
18.56 26.48 
9 50.1 kgs 10th day 
of  cycle 
18.12 25.20 
APPENDIX B   (Continued) 
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Subject Weight Time V02 ml/kg/min V02 ml/kg/min 
at  300 Kpm at 600 Kpn 
10 
10 
10 
11 
11 
11 
49.5 kgs 
48.6 kgs 
48.6 kgs 
48.7 kgs 
53.6 kgs 
53.2 kgs 
53.2 kgs 
26th day 
of   cycle 
4th day 
of  cycle 
10th day 
of   cycle 
26th day 
of  cycle 
4th day 
of   cycle 
10th day 
of  cycle 
26th day 
of  cycle 
21.51 
20.60 
21.94 
21.05 
19.54 
18.05 
19.40 
31.15 
28.82 
31.93 
33.90 
32.36 
26.80 
29.77 
All V02 measurements were   converted to standard temperature  and pressure. 
